Animal Genetics Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2023

Market Scenario:

Animal genetics is a branch of genetics that pacts with the study of genetic variation and inheritance, primarily for domestic and wild animals. The Animal Genetics Market is expected to witness tremendous growth owing to as increased adoption of genetic services to prevent genetic diseases and business loss, and rising acceptance of advanced genetic technologies. Other key factors such significant investments in R&D and expansions undertaken by key players are contributing towards the growth of the market. However, challenges such as need for specific breeding programs for breeds with inferior economic performance, and economic sustainability in local breeds is likely to curb the market growth during the forecast period.

For the commercial level, animal genetics is used for services such as DNA typing, genetic disease testing, and genetic trait testing. This methodology uses hybrid population, ontogenetic, and cytological studies for determining the genetic hybridizations. For instance, a genetically modified cow might be able to produce more milk and can be less prone to common cattle diseases, such as clostridial disease, bovine respiratory disease complex, etc., thus, effectively increasing overall profit of the cattle farmers 

The Global Animal Genetics Market size is projected to register a CAGR of 8.4% over the forecast period.

The key factor responsible for influencing this market is increasing consumption of animal-derived protein, growing global population and rapid urbanization, and growing focus on identifying superior breeds have aided the growth of the toxicology testing market. However, factors such as, the high cost of animal testing, stringent regulatory framework for genetic engineering, and lack of skilled professionals and are expected to restrict the market growth during the forecast period.

Key players:

• Neogen Corporation (US),
• Genus (UK),
• URUS (US),
• EW Group (Germany),
• Groupe Grimaud (France),
• CRV Holding B.V. (The Netherland),
• Topigs Norsvin (Netherlands),
• Zoetis (US),
• Envigo (US)
• Hendrix Genetics BV (The Netherland),
• Animal Genetics (US),
• Alta Genetics (US),
• vetGen (US)

Segmentation:The Animal Genetics Market Global is segmented into animal genetic products, services, and end-user. The Animal Genetics Market, by animal genetic products, the market is segmented into genetic materials and live animals. The live animals are further bifurcated into poultry, bovine, porcine, canine and others. The genetic materials are sub-segmented into semen and embryo. On the basis of services, the animal genetics market is bifurcated into genetic disease tests, DNA typing, gene trait tests, and others. On the basis of end-user, the market is segmented into veterinary hospitals & clinics, diagnostic centers, research centers and institutes, and others

Regional Market Summary 

The Americas is the largest in the market owing to the high acceptance of animal genetics in research, the development in research expenditure along with the increasing acquisition by the market players are also accountable for the growth of the animal genetics market. For instance, in 2018, Neogen completed the acquisition of Livestock Genetic Services, a firm that specializes in genetic evaluations and data management for cattle-breeding organizations. This strategy enhances the company’s in-house genetic evaluation capabilities and further expands the company’s global network of animal genomics laboratories.

The European region is the second largest animal genetics market over the forecast period due to high consciousness about animal wellbeing coupled with increased expenditure on veterinary services in the region. As per a report by the European Pet Food Industry Federation, more than 75 million households in Europe own a pet.

The Asia Pacific region is likely to develop at the uppermost CAGR for the animal genetics market in the years to come. Moreover, the rising veterinary care services both at the veterinary hospital and at community level are expected to influence the market in a positive way.

The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, there has been an increasing demand for test accuracy and consistency among end-users and the government in this region that is enhancing the adoption of animal genetic technology in this region.

Epilepsy Diagnosis & Treatment Market Opportunities, Drivers, Manufacturers, Analysis And Forecasts Till 2023

Synopsis of the Global Epilepsy Diagnosis & Treatment Market
Increasing prevalence of epilepsy, rising number of traumatic brain injury cases, growing geriatric population, and rising healthcare expenditures are the major drivers for the global epilepsy diagnosis and treatment market trends. However, high cost of therapeutic surgeries, low per capita healthcare expenditure, and lack of awareness for the disease in emerging economies are estimated to restrain the market growth during the projected period. The global epilepsy diagnosis and treatment market is estimated to grow at an approximate CAGR of 6.3% during the forecast period.
Segmentation
The global epilepsy diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, and end-user. On the basis of type, the market is segmented into idiopathic, cryptogenic, symptomatic, and others. On the basis of diagnosis, the market is segmented into neurological exam, blood test, imaging, and others. The imaging segment is sub-segmented into electroencephalogram, computerized tomography, magnetic resonance imaging, positron emission tomography, and others. On the basis of treatment, the market is segmented into medication, surgery, brain stimulation, and others. The medication segment is sub-segmented into acetazolamide, carbamazepine, clobazam, and others. The surgery segment is sub-segmented into hemispherectomy, corpus callosotomy, resection surgery, and others. The brain stimulation segment is sub-segmented into deep brain stimulation, responsive neurostimulation, and others. On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
Regional Analysis
The Americas dominate the global epilepsy diagnosis and treatment market, which can be attributed to the presence of a well-developed healthcare sector and huge patient population within the region. Moreover, increasing number of head trauma cases boosts the American market. Europe holds the second largest market share owing to the availability of funds for research, presence of a well-developed healthcare sector, and government support. Followed by Europe, the Asia Pacific region is projected to be the fastest growing region for the global epilepsy diagnosis and treatment market. Presence of developing healthcare sector, along with emerging economies of the Asia Pacific region boosts the market growth. The Middle East & Africa has the least share in the global epilepsy diagnosis and treatment market, owing to the low per capita healthcare expenditures, lack of awareness for the disease, and stringent government policies, especially in the African region. On the other hand, the Middle East region within the Middle East & Africa is estimated to be fastest growing region due to growing healthcare expenditures and presence of the developed economies, such as Kuwait, Qatar, Dubai, and others.
Key Players
The key players for the global epilepsy diagnosis and treatment market are Pfizer, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), UCB Pharma Ltd. (U.K), Abbott (U.S.), GlaxoSmithKline plc (U.K), Novartis International AG (Switzerland), Sanofi S.A. (France), Shire (Republic of Ireland), Medtronic (U.S.), NeuroWave Systems Inc. (U.S.), Natus Medical Incorporated. (U.S.), Siemens Ltd. (Germany), and others.

Global Ebstein’s Anomaly Market Solid Segment Analyzed By Latest Trends, Growth Rate And 2023 Insight

Market Scenario:

Ebstein's anomaly is a rare congenital disease that occurs due to improper development of the tricuspid valve in the first eight weeks of fetal growth. This disorder occurs when the tricuspid valve that divides the two chambers of the right side of the heart does not form correctly.

The global Ebstein’s Anomaly market is driven by the increasing number of congenital heart diseases and growing population; growing market players has increased the scope of Ebstein’s Anomaly market. Technological advancements, owing to which new and advanced products are being launched in the market, is another factor propelling the growth of this market.

Ebstein's anomaly may be due to many factors, including genetics and the environment. Children born in a family with a history of heart defects may be more likely to have Ebstein's anomaly. The mother's exposure to certain medications, such as lithium, can lead to Ebstein's anomaly in the child.

However, varied stringency of regulatory procedures across the globe and the presence of complex regulatory procedures may hinder the growth of this market.

The global Ebstein’s Anomaly market share is expected to grow at a CAGR of 9.0% during the forecast period.

Key Players                                                                                                         

Some of the key players in fungal eye infection market are Ebstein’s Anomaly market are Abbott Vascular, Boston Scientific Corporation, Cordis Corporation, Edwards Lifesciences, Ge Healthcare, Gore Medical, Medtronic, Inc., Numed, Inc., Siemens Healthcare, St. Jude Medical, and Toshiba Corporation among others.

Segmentation                                                                                                                                            

The global Ebstein’s Anomaly market is segmented on the basis of treatment, diagnosis and end users.

On the basis of diagnosis Ebstein’s Anomaly market is segmented into echocardiogram, electrocardiogram (ECG) chest x-ray, cardiac MRI, Holter monitor, pulse oximetry, exercise stress test, electrophysiology study, and cardiac catheterization.

On the basis of the treatment, the market is segmented medications and surgical treatment. Surgical Treatment is further segmented into tricuspid valve repair, tricuspid valve replacement, closure of the atrial septal defect, and maze procedure.

On the basis of end users, the market is segmented into hospitals & surgical centers, and specialty clinics.

Regional Analysis

North America Ebstein’s Anomaly market is rapidly growing in the American region. On a regional basis, the Americas is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of congenital disorders and growing  population has increased the scope for the Ebstein’s Anomaly market in North America. According to CDC (Centre for Disease Control), it was estimated that about 1 million U.S. children and about 1.4 million U.S. adults were living with CHDs.  Additionally, CHDs affect nearly 1% of―or about 40,000―births per year in the United States.

Europe is the second largest market and holds a healthy share in the global Ebstein’s Anomaly market. The European market is expected to grow steadily during the forecast period owing to the skilled professionals and availability of advanced and accessible treatment facilities. Additionally, wide research and development activities for the treatment of rare disease and increasing government funding boost the market growth.  

Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes is the major driver for the market growth. India is the fastest growing region owing to the increasing population. Rising awareness about the health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drives the market.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.

Worldwide Dry Eye Syndrome Market Ready To Set Outstanding Growth From 2019 To 2023

Global Dry Eye Syndrome research report, by type (evaporative, aqueous), by diagnosis (schirmer test, eye exam), treatment (nutritional supplements, surgery), distribution channel (hospital pharmacies) end user (hospitals) - global forecast till 2023

Increasing geriatric population, rising prevalence of the diseases like diabetes, rheumatoid arthritis, growing per capita healthcare expenditure, and changing lifestyle are the major drivers for the market growth. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle and low income countries are estimated to restrain the market growth during the forecast period. 

The global dry eye syndrome market growth is expected to advance with an approximate CAGR of 6.6% during the forecast period.

According to the World Health Organization in 2016, approximately 422 million adults were globally affected by diabetes in 2014, as compared to 108 million in the 1980’s. Moreover, in 2014, it was estimated that the global prevalence of diabetes was estimated to be around 8.5%. Additionally, rising per capita healthcare expenditure, and changing lifestyle boosts the market. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle-and low-income countries are restraining the market. 

Tears provide lubrication, limits the risks of eye infections, washes away the foreign matter, thus, are helpful in keeping the surface of the eyes smooth and clear. Dry eye syndrome is a medical condition in which eyes’ lubrication is hindered by the unavailability of tears. Under normal condition, during excessive production, tears flow into the small drainage ducts of the inner corners of the eyes, followed by draining back into the nose. Sometimes when the production of tears and drainage is not balanced, it can result into dry eye syndrome. Eye redness, sensitivity to light, watery eyes, eye fatigue are some of the common symptoms of the disease. Increasing geriatric population, rising prevalence of diseases like diabetes, rheumatoid arthritis, and others are estimated to be the major drivers for the market growth.

Key Players

The key players for the global dry eye syndrome are Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaceutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (U.S.), Acadia Pharmaceutical (U.S.), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT pharmaceuticals (New Zealand), Novaliq GmBh (Germany), Auven therapeutics (U.S.), and others.

Segmentation

The global dry eye disease market is segmented on the basis of the type, diagnosis, treatment, distribution channel and end user.

On the basis of the type, the market is segmented into evaporative dry eye syndrome aqueous dry eye syndrome, and others. On the basis of the diagnosis, the market is categorized into Schirmer test, eye exam, and others.  On the basis of the treatment, the market is segmented into nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment is sub-segmented into oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segments segement is sub-segmented into tetracyclines, corticosteroids, and others. The surgery segment is sub-segmented into punctal occlusion, intense pulsed light therapy, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.  On the basis of the end users, the market is segmented into hospitals, clinics, home care, and others.

Regional Analysis

The Americas dominates the global dry eye syndrome market owing to the presence of a well-developed healthcare sector, huge patient population, and increasing healthcare expenditure. Moreover, the presence of the major market players like Johnson & Johnson Vision, Auven therapeutics, Acadia Pharmaceutical, and others within the region boosts the market growth. Europe stands second in the dry eye syndrome market. This is attributed to the increasing availability of funds for research, a well-developed healthcare sector, huge patient and growing geriatric population. The Asia Pacific region is estimated to be the fastest growing region for the market. Economies like India, China, Australia and others within the region have huge patient population, rising healthcare expenditure facilitating the market growth. On the other hand, the Middle East & Africa has the least share in the global dry eye syndrome. Low per capita healthcare expenditure, stringent government policies, especially within the African region restrains the market growth within the region. The Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure.

World Diastematomyelia Market Estimation Of Top Key Players Shares, Revenue, Analysis And Forecasts Till 2023

Market Scenario

Diastematomyelia is a rare anomaly resulting in the vertical splitting of the spinal cord. Females are more susceptible to this disease than males. According to the World Health Organization (2015), 1 in 2000 people suffers from this disease. However, during the last few years, the prevalence rate is increasing continuously. Increasing number of patients suffering from the disease, rising geriatric population and rising government support for research & development have driven the growth of the market. Moreover, rising demand for the better treatment, and changing lifestyle habits have fuelled the growth of the market. However, the cost of the surgery is too high and is not affordable to the people in developing region. Thus, the high cost of treatment may restrain the market.

A number of diagnostic procedures are available in the market for the diagnosis of the diastematomyelia. Increasing healthcare expenditure and rising government support have supported the growth of the market. According to the Boston Children's Hospital, in 2015, 5% of children across the globe were suffering from sustain spinal cord injuries. Furthermore, rapid development in the imaging technology and continuous improvement in the medical services have fuelled the market growth. The cost associated with the surgeries is very high which is not affordable for the people in developing region. Thus, high cost of surgeries, and lack of the precise treatment may restrain the growth of the diastematomyelia market trends.

The Global Diastematomyelia Market is expected to grow at a CAGR of 8.3% during forecast period 2017-2023.

Key players

The major key players in the global diastematomyelia market: 3M (US), GlaxoSmithKline PLC (U.K), Pfizer Inc. (U.S.), Lineage Medical, Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), Bristol-Myers Squibb and Company (U.S.), B. Braun (Germany), Stryker Corporation (U.S.), Argon Medical Devices, Inc (the Netherlands), Cook Medical (U.S.)

SegmentationThe global diastematomyelia market is segmented on the basis of types, host, therapy, and end users.

On the basis of type, the market is segmented into dual dural sac (type 1), and single sac (type 2).

On the basis of host, the market is segmented into children and adults.

On the basis of therapy, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into imaging techniques, and prenatal ultrasound. Imaging techniques are further categorised into Plain X-ray, CT, MRI and others. The therapy is further segmented into surgical intervention, scoliosis surgery, decompression (surgery), and others.

On the basis of end users, the market is segmented into hospital, clinics, ambulatory centers, and others.

Regional Analysis

Asia Pacific is the fastest growing region in the global diastematomyelia market owing to the presence of huge patient pool, rapidly developing economies, and increasing demand for the better treatment options. Majority of the market is driven by India and China owing to huge patient population.

The Americas dominates the global diastematomyelia market owing to large patient population. According to the Brain and Spinal Cord Injury Rehabilitation, in 2015, over 259,000 people in the U.S. were suffering from spinal cord injury. Increasing number of patients suffering from diastematomyelia and other spinal disease have driven the growth of the Americas diastematomyelia market. Additionally, high per capita income and increasing government support for research & development will fuelled the growth of the market. Diastematomyelia is considered as a rare diseases thus, government and other private companies are trying to create awareness among the people by conducting different seminars. Increasing awareness among people regarding the disease and well-developed technology will create opportunities for the development of the market.

Europe accounts for the second largest diastematomyelia market, which is followed by Asia Pacific. Availability of funds for research, huge geriatric population, and government support for research & development projected to drive the market in Europe. The U.K and Germany are the major contributors for the market.

Whereas, the Middle East & Africa owns the least share of the global diastematomyelia market due to the presence of poor economy, especially, in the Africa region. The market of this region is dominated by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. However, Africa region shows the fastest growth for the market.

World Bone Density Test Market Top Key Players Shares, Revenue, Analysis And Forecasts To 2023

Bone Density Test Market By Type (Central Dual-Energy X-Ray Absorptiometry (DXA), Radiographic Absorptiometry), Indication (Osteoporosis, Hyperthyroidism,), Device (Central DEXA Scan Machine), End User (Hospitals) - Global Forecast Till 2023

Recognizing the exponential growth, the market perceives currently and gauging the potential the market holds to grow in the years to come. Recent technological advancements and bone density test market trends have boosted the Bone Density Test market growth, increasing the uptake of bone density test.  Besides, increasing prevalence of osteoporosis, osteopenia, hyperthyroidism, and increasing demand for portable bone testing devices foster the market growth.  Moreover, the demand for diagnosis and treatment measures for osteoporosis escalates the market growth of the bone density test on the global platform.

Market Research Future (MRFR), in its recently published market forecast asserts that the global bone density test market will grow exponentially by 2023, registering approximately 7.2% CAGR during the review period (2017 – 2023).

Additional factors substantiating the market growth include the demand for technologically advanced devices and growing geriatric populace.  Also, substantial technological strides being made in electronic monitoring devices and substantial investments transpired into R&D activities are in turn, paying off well, expanding the market size.

Bone density test provides more of a high-level overview and in-depth details on more specific aspects of bone health alongside indicating current and potential health risks such as Low bone mineral density, Osteoporosis, and Hyperthyroidism.  A stress fracture or other bone issue is often the initial reason that can cause impaired bone health and can affect bone density in the future. All these factors indicate that a bone is not as strong as normal bone and places that are at risk for stress fractures or other broken bones.

Furthermore, the ever-increasing population that is increasingly adopting the sedentary lifestyle and urbanization are supporting the market growth. Improving economic conditions are providing impetus to the market growth, increasing the healthcare expenditures and availing rapid access to the excellent health care.

On the other hand, limited or no awareness of the advantages of bone density test is impeding the market growth.  Also, the unmet clinical needs coupled with the unavailability of external funding are acting as a headwind to the market growth, especially in the developing regions. Nevertheless, increasing demand for portable and hand-held diagnostic devices alongside the augmenting demand for the bone density test in the diagnostics to obtain fastest & accurate results is expected to fuel the market growth. 

Competitive Analysis

The market for bone density test appears fragmented and fiercely competitive due to many large and small players churning the competition in the market.  Through the strategic partnership, acquisition, expansion, product & technology launch, and collaboration, these players try to gain the competitive edge.

The global bone density test market is led by some of the fervent players like

• Hologic Inc. (U.S),
• General Electric Company (U.S.),
• BeamMed Ltd.  (Israel),
• Osteosys Corp (South Korea),
• Swissray (U.S.),
• DMS Imaging (France),
• Osteometer Meditech Inc. (U.S),
• Medonica Co. LLTb (South Korea),
• Lone Oak Medical Technologies, LLC (U.S.).

Global Bone Density Test Market – Segments

The market can be segmented into five key dynamics for the convenience of understanding;

By Types                   : Central Dual-Energy X-Ray Absorptiometry (DXA), Peripheral Tests {peripheral dual-energy X-ray absorptiometry (pDXA), quantitative ultrasound (QUS), peripheral quantitative computed tomography (pQCT), others} and Radiographic Absorptiometry among others.

By Indications    : Osteoporosis, and Hyperthyroidism, others.

By Devices               : Central DEXA Scan Machine and others.

By End-Users          :  Hospitals, clinics, and diagnostic centers, among others.

By Regions              :  North America, Europe, APAC and the Rest-of-the-World (RoW).

Regional Analysis

The North American region is estimated to retain its dominance over the global bone density test market with the largest market share. A well-developed healthcare sector, increasing prevalence of diseases and disorders related to bones such as osteoporosis, osteopenia, and hyperthyroidism along with the high per capita healthcare expenditures drive the market growth in the region. The region is expected to create a substantial revenue pocket registering a strong CAGR throughout the forecast period (2017-2023). Furthermore, the presence of prominent market players especially in the U.S. & Canada impacts the market growth positively. 

The European region accounts for the second-largest market for bone density test, emerging as another lucrative market, globally. The U.K., backed by its sizeable vast bone density test market and Germany with its vast medical device industry is expected to drive the market growth in the region. Favorable governmental support and initiatives drive the growth in the market extensively. The proliferating healthcare sector in the region, backed by the resurging economy is fostering the market growth radiantly.

The Asia Pacific region is emerging as a promising market for bone density test owing to the rising prevalence of osteoporosis in women after menopause. Furthermore, increasing awareness towards women healthcare and nutrition influences the market growth. Changing lifestyle and overall development of medical device industry supports the growth of the market in the region.  Besides, the increasing healthcare expenditures and favorable government policies of developing economies like India and China substantiate the market growth in the APAC region.

Hip Tendinitis Market Strategies And Competitive Analysis, Forecast Till 2023

Market Scenario:

The rising geriatric population is a major factor expected to drive the expansion of the hip tendinitis market over the next few years. The population of older adults is increasing at a higher rate than any other age group as analyzed by the World Health Organization (WHO). Its statistical observations further suggest that the number of people over 60 years is anticipated to exceed 2 billion mark by the end of 2050. It is projected to act as a growth catalyst for the hip tendinitis market over the next couple of years.

Hip tendonitis is a condition where the tendons present in the hip and pelvis joints that support the bodyweight get damaged. Multiple factors have been recognized that triggers the disease and is likely to affect a larger section of the population in the years to come. Market Research Future (MRFR)’s assessment has asserted that the global hip tendinitis market growth is expected to expand at a CAGR of 4.55% during the forecast period 2017 to 2023. It is also expected to scale a decent valuation by the end of the forecast period.

The concerns raised by the sedentary lifestyle is motivating the masses to shift towards sports and other physical activities for maintaining health and avoiding cardiovascular diseases. However, a drastic increase in injuries during sports has been observed in the recent years. This is one of the major factors responsible for the expansion of the hip tendinitis market currently. It is anticipated to has a similar influence on the growth pattern of the market in the forthcoming years.

Some of the other factors that are likely to boost the growth pace of the hip tendinitis market in the forthcoming future are lack of exercise, research & development, and increasing patient population of rheumatoid arthritis & diabetes. This, is projected to encourage the key players to focus on the development of more effective drugs and diagnosis, thus, augmenting the hip tendinitis market in the foreseeable future.

Key players for global hip tendinitis market

• Almatica Pharma, Inc
• AstraZeneca
• Bayer AG
• Boehringer Ingelheim Pharmaceuticals, Inc
• Merck & Co., Inc
• Pfizer
• Abbott
• GlaxoSmithKline plc
• Teva Pharmaceuticals
• Lupin Pharmaceuticals, Inc.
• Geri-Care Pharmaceuticals.
• Perrigo Company

Segmentation

The global hip tendinitis market is segmented on the basis of types, treatment, and end users.

On the basis of types, the market is segmented into internal snapping hip, external snapping hip, and intra-articular snapping hip.

On the basis of treatment, the market is segmented into diagnosis and therapy. The diagnosis is further segmented into physical exam, imaging tests, and others. Imaging test is further segmented into ultrasound, magnetic resonance imaging (MRI) scans, and others. The therapy is segmented into pharmacological, non-pharmacological, shock wave or surgery, medical devices, and others. The pharmacological therapy is further segmented into OTC drugs, corticosteroids injections, platelet-rich plasma (PRP), and others. The medical devices are further segmented into mechanical band, support tape, pre-cut strips, continuous rolls, and others.

On the basis of end users, the market is segmented into hospitals & clinics, medical research centers, academic institutes, and others. 

Regional Analysis

The global hip tendinitis market is dominated by America owing to the presence of huge geriatric population and continuous increasing number of diabetic patients. As per the report published by the population reference bureau, in 2015, the number of Americans ageing over 65 were 46 million, which is expected to reach over 98 million by 2060. Furthermore, increasing number of patients suffering form rheumatoid arthritis, changing lifestyle, and huge healthcare spending have boosted the growth of the market in America. According to the American Diabetes Association, over 30.3 million Americans population were suffering from diabetes in 2015. Additionally, increasing awareness among the people regarding different types of diseases and increasing government support is likely to contribute to the growth of the market during the review period 2017-2023.

Europe accounts for the second largest hip tendinitis market, which is followed by Asia Pacific. According to the Eurostat, in 2016, 19.2% of total European population were over age 65 years. Increasing geriatric population and adoption of sports by the people may drive the market growth. Moreover, availability of funds for research, and government support for research & development are expected to fuel the market growth.

Asia Pacific is the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, and the presence of huge opportunity in the market. On the other hand, the Middle East & Africa holds the least share in the global hip tendinitis market due to presence of poor economy, especially, in African region. The Middle East holds the major share of the Middle East & African market owing to the well-developed healthcare sector and huge healthcare expenditure. 

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/hip-tendinitis-market-4764